Axsome Therapeutics

Yahoo Finance • 5 days ago

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story

Yahoo Finance • 22 days ago

How Investors May Respond To Axsome Therapeutics (AXSM) Showcasing Late-Stage CNS Pipeline Data at Psych Congress

Axsome Therapeutics recently presented six clinical and real-world neuroscience data posters at the 38th Annual Psych Congress in San Diego, with a focus on major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstruct... Full story

Yahoo Finance • 25 days ago

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its... Full story

Yahoo Finance • 29 days ago

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company (NYSE: GM), DocGo Inc. (NASDAQ: DCG... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in t... Full story

Yahoo Finance • 2 months ago

ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment

By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by prelimi... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Axsome Therapeutics beats Q2 2025 forecasts

Axsome Therapeutics Inc. (AXSM) reported its second-quarter 2025 earnings, surpassing Wall Street expectations. The company posted an earnings per share (EPS) of -$0.97, outperforming the forecast of -$1.06. Revenues reached $150 million,... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading

Axsome Therapeutics Inc (NASDAQ:AXSM [https://www.chartmill.com/stock/quote/AXSM]) reported second-quarter 2025 financial results, delivering revenue that exceeded analyst expectations while narrowing its earnings per share (EPS) loss comp... Full story

Yahoo Finance • 2 months ago

Stocks Set to Open Higher as Investors Bet on Fed Rate Cuts

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.64%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.77% this morning, po... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Transocean Ltd. (RIG [https://seekingalpha.com/symbol/RIG]) * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * BioNTech SE (BNTX [https://seekingal... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz

[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • 3 months ago

Top rated and bottom rated stocks according to 3 key drivers of performance – UBS

[Top Prospects Most Profitable Stock Market Best Investments 3d Illustration] iQoncept/iStock via Getty Images UBS analysts listed top and bottom-ranked stocks based on a key set of drivers for equities, they named REVS. UBS’s REVS frame... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontie... Full story

Yahoo Finance • 4 months ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease... Full story

Yahoo Finance • 4 months ago

Axsome therapeutics' general counsel sells $2.28 million in stock

Hunter R. Murdock, General Counsel at Axsome Therapeutics, Inc. (NASDAQ:AXSM), sold a total of 22,500 shares of common stock for approximately $2.28 million, between June 16 and June 18, 2025. The sales were executed at weighted average pr... Full story

Yahoo Finance • 4 months ago

Axsome Therapeutics' SWOT analysis: stock's potential in CNS market

Axsome Therapeutics, Inc. (NASDAQ:AXSM), with a market capitalization of $5.14 billion and impressive year-to-date returns of 23%, has positioned itself as a prominent player in the central nervous system (CNS) disorders market, with a div... Full story

Yahoo Finance • 4 months ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, includin... Full story

Yahoo Finance • 4 months ago

Axsome Launches SYMBRAVO, A New Dual-Action Prescription Migraine Treatment In The U.S.

(RTTNews) - Axsome Therapeutics, Inc. (AXSM) has announced the U.S. prescription availability of SYMBRAVO, a new oral medication combining meloxicam and rizatriptan for the acute treatment of migraine with or without aura in adults. The t... Full story